S Squared Technology LLC Raises Holdings in Krystal Biotech, Inc. $KRYS

Key Points

• S Squared Technology LLC increased its stake in Krystal Biotech, Inc. by 2,000 shares to a total of 97,215 shares, making it the firm's largest holding at 9.0% of its investment portfolio.
• Krystal Biotech recently reported an earnings per share (EPS) of $1.29, surpassing the consensus estimate of $1.08, contributing to a market capitalization of $4.20 billion.
• The stock is receiving mixed reviews with seven analysts rating it as a Buy and one as a Hold, suggesting a current average target price of $210.38.

S Squared Technology LLC raised its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 97,215 shares of the company's stock after purchasing an additional 2,000 shares during the period. Krystal Biotech accounts for approximately 9.0% of S Squared Technology LLC's holdings, making the stock its biggest position. S Squared Technology LLC owned 0.34% of Krystal Biotech worth $17,528,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Brooklyn Investment Group lifted its position in shares of Krystal Biotech by 291.7% in the first quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after buying an additional 105 shares in the last quarter. Twin Tree Management LP bought a new stake in Krystal Biotech in the 1st quarter worth approximately $29,000. Fifth Third Bancorp raised its holdings in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock worth $58,000 after acquiring an additional 177 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Krystal Biotech during the 1st quarter valued at approximately $74,000. 86.29% of the stock is owned by institutional investors.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 1,389 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider directly owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. This trade represents a 0.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 49,800 shares of company stock valued at $7,487,943 in the last quarter. Corporate insiders own 13.70% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KRYS shares. HC Wainwright restated a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a research report on Friday, August 22nd. Citigroup restated a "neutral" rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Bank of America decreased their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Finally, Chardan Capital dropped their price target on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research report on Friday, August 22nd. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $209.00.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded down $0.68 during trading on Friday, hitting $143.68. The stock had a trading volume of 350,777 shares, compared to its average volume of 255,846. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $207.84. The firm's fifty day simple moving average is $146.81 and its 200-day simple moving average is $152.43. The stock has a market cap of $4.16 billion, a PE ratio of 29.20 and a beta of 0.66.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The company had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).